BridgeBio Pharma Announces Proposed Public Offering of Common Stock
March 04 2024 - 4:17PM
BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a
commercial-stage biopharmaceutical company focused on genetic
diseases and cancers, announced today that it has commenced an
underwritten public offering of $250 million of shares of its
common stock. BridgeBio also intends to grant the underwriters a
30-day option to purchase up to an additional $37.5 million of
shares of its common stock. All of the shares in the proposed
offering are to be sold by BridgeBio.
J.P. Morgan, Cantor Fitzgerald & Co. and Mizuho are acting
as joint book-running managers for the proposed offering. Raymond
James is acting as lead manager. The proposed offering is subject
to market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the proposed offering.
The shares of common stock are being offered by BridgeBio
pursuant to an effective shelf registration statement on Form
S-3ASR that was previously filed with the U.S. Securities and
Exchange Commission (SEC) on May 4, 2023 and automatically became
effective upon filing. The offering is being made only by means of
a prospectus supplement and the accompanying prospectus that will
form a part of the registration statement. A preliminary prospectus
supplement and accompanying prospectus relating to and describing
the terms of the offering will be filed with the SEC and may be
obtained, when available, from J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
New York 11717, by telephone at (866) 803-9204, or by email at
prospectus-eqfi@jpmorganchase.com; Cantor Fitzgerald & Co.,
Attention: Capital Markets, 110 East 59th Street, 6th Floor, New
York, NY 10022, or by email at prospectus@cantor.com; Mizuho
Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue
of the Americas, 3rd Floor, New York, New York 10020, by telephone
at 1-212-205-7602 or by email at US-ECM@mizuhogroup.com; or by
accessing the SEC’s website at www.sec.gov. The final terms of the
proposed offering will be disclosed in a final prospectus
supplement to be filed with the SEC.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About BridgeBio
BridgeBio is a commercial-stage biopharmaceutical company
founded to discover, create, test and deliver transformative
medicines to treat patients who suffer from genetic diseases and
cancers with clear genetic drivers. BridgeBio’s pipeline of
development programs ranges from early science to advanced clinical
trials. BridgeBio was founded in 2015 and its team of experienced
drug discoverers, developers and innovators are committed to
applying advances in genetic medicine to help patients as quickly
as possible.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding BridgeBio’s anticipated public offering. The words “may,”
“might,” “will,” “could,” “would,” “should,” “expect,” “plan,”
“anticipate,” “intend,” “believe,” “expect,” “estimate,” “seek,”
“predict,” “future,” “project,” “potential,” “continue,” “target”
and similar words or expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
Any forward-looking statements in this press release, such as
the intended offering terms, are based on management’s current
expectations and beliefs and are subject to a number of risks,
uncertainties and important factors that may cause actual events or
results to differ materially from those expressed or implied by any
forward-looking statements contained in this press release,
including, without limitation, uncertainties related to market
conditions, the completion of the public offering on the
anticipated terms or at all and BridgeBio’s intention to grant the
underwriters an option to purchase additional shares. These and
other risks and uncertainties are described in greater detail in
the section entitled “Risk Factors” in BridgeBio’s Annual Report on
Form 10-K for the year ended December 31, 2023, as well as
discussions of potential risks, uncertainties, and other important
factors in BridgeBio’s other filings with the SEC, including those
contained or incorporated by reference in the preliminary
prospectus supplement and accompanying prospectus related to the
proposed public offering expected to be filed with the SEC. In
addition, any forward-looking statements contained in this press
release represent the BridgeBio’s views only as of the date hereof
and should not be relied upon as representing its views as of any
subsequent date. BridgeBio explicitly disclaims any obligation to
update any forward-looking statements. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
BridgeBio Contact:Vikram
Balicontact@bridgebio.com(650) 789-8220
BridgeBio Pharma (NASDAQ:BBIO)
Historical Stock Chart
From Apr 2024 to May 2024
BridgeBio Pharma (NASDAQ:BBIO)
Historical Stock Chart
From May 2023 to May 2024